ES2612889T3 - Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos - Google Patents

Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos Download PDF

Info

Publication number
ES2612889T3
ES2612889T3 ES09796016.5T ES09796016T ES2612889T3 ES 2612889 T3 ES2612889 T3 ES 2612889T3 ES 09796016 T ES09796016 T ES 09796016T ES 2612889 T3 ES2612889 T3 ES 2612889T3
Authority
ES
Spain
Prior art keywords
cells
metastasis
oncolytic adenoviral
region
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09796016.5T
Other languages
English (en)
Spanish (es)
Inventor
Akseli Hemminki
Anna Kanerva
Vincenzo Cerullo
Sari Pesonen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targovax Oy
Original Assignee
Targovax Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20080671A external-priority patent/FI20080671A0/fi
Application filed by Targovax Oy filed Critical Targovax Oy
Application granted granted Critical
Publication of ES2612889T3 publication Critical patent/ES2612889T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES09796016.5T 2008-12-22 2009-12-21 Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos Active ES2612889T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
FI20080671A FI20080671A0 (fi) 2008-12-22 2008-12-22 Onkolyyttiset virukset
FI20080671 2008-12-22
FI20095466A FI121508B (fi) 2008-12-22 2009-04-27 Adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä
FI20095466 2009-04-27
US58597109A 2009-09-29 2009-09-29
US585971 2009-09-29
PCT/FI2009/051025 WO2010072900A1 (en) 2008-12-22 2009-12-21 Oncolytic adenoviral vectors and methods and uses related thereto

Publications (1)

Publication Number Publication Date
ES2612889T3 true ES2612889T3 (es) 2017-05-19

Family

ID=44502296

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09796016.5T Active ES2612889T3 (es) 2008-12-22 2009-12-21 Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos

Country Status (20)

Country Link
EP (1) EP2379586B1 (cg-RX-API-DMAC7.html)
JP (2) JP2012513209A (cg-RX-API-DMAC7.html)
KR (1) KR101761094B1 (cg-RX-API-DMAC7.html)
CN (1) CN102264760B (cg-RX-API-DMAC7.html)
AU (1) AU2009332883B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0924123B8 (cg-RX-API-DMAC7.html)
CA (1) CA2748180C (cg-RX-API-DMAC7.html)
CY (1) CY1120039T1 (cg-RX-API-DMAC7.html)
DK (1) DK2379586T3 (cg-RX-API-DMAC7.html)
ES (1) ES2612889T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170165T1 (cg-RX-API-DMAC7.html)
HU (1) HUE031689T2 (cg-RX-API-DMAC7.html)
LT (1) LT2379586T (cg-RX-API-DMAC7.html)
PL (1) PL2379586T3 (cg-RX-API-DMAC7.html)
PT (1) PT2379586T (cg-RX-API-DMAC7.html)
RU (1) RU2520823C2 (cg-RX-API-DMAC7.html)
SG (1) SG173432A1 (cg-RX-API-DMAC7.html)
SI (1) SI2379586T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010072900A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201104224B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102858959B (zh) 2009-12-10 2016-02-24 渥太华医院研究院 溶瘤弹状病毒
CA2812093A1 (en) * 2010-09-24 2012-03-29 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
BR112013006669A2 (pt) * 2010-09-24 2019-09-24 Oncos Therapeutics Oy vetores adenovirais oncolíticos e métodos e usos relacionados aos mesmos
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
US10238698B2 (en) 2012-01-25 2019-03-26 Dnatrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
RU2684211C2 (ru) 2013-02-21 2019-04-04 Тёрнстоун Лимитед Партнершип Композиция вакцины
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
CA2909432C (en) * 2013-04-18 2025-11-18 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
US12421502B2 (en) 2013-04-18 2025-09-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
US10350275B2 (en) * 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
ES2987442T3 (es) * 2015-05-04 2024-11-14 Theriva Biologics S L Adenovirus oncolíticos con mutaciones en epítopos de adenovirus inmunodominantes y su uso en el tratamiento del cáncer
FI127460B (en) * 2016-01-15 2018-06-29 Targovax Oy Combining adenovirus and chemotherapeutic agents for treating cancer
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3426271B1 (en) 2016-03-10 2025-08-27 CG Oncology, Inc. Methods of treating solid tumors by combination therapy
ES2845690T3 (es) 2016-09-12 2021-07-27 Targovax Oy Combinación de adenovirus e inhibidores de punto de control para el tratamiento del cáncer
EP3534923A4 (en) * 2016-11-01 2020-05-27 DNAtrix, Inc. COMBINATION THERAPY FOR THE TREATMENT OF BRAIN CARCINOMAS
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
KR20190104051A (ko) * 2017-01-06 2019-09-05 스타빌리테크 바이오파마 리미티드 바이러스
AU2018251987B2 (en) 2017-04-14 2024-11-28 Cg Oncology, Inc. Methods of treating bladder cancer
NZ758626A (en) 2017-04-21 2023-09-29 Baylor College Medicine Oncolytic virotherapy and immunotherapy
AU2018273963B2 (en) 2017-05-25 2023-07-20 University Of Central Florida Research Foundation, Inc. Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
US11896635B2 (en) 2017-11-08 2024-02-13 Kagoshima University Oncolytic virus (oncolytic immunotherapy) capable of effectively treating even metastatic cancer while ensuring safety, with expression control system providing optimal expression level of mounted immunogenic gene
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
EP3725323A1 (en) 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
EP3725888A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing peptidylarginine deiminase and tissue inhibitor of metalloproteinase
EP3725322A1 (en) 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing granzyme and perforin
US20240293487A1 (en) * 2020-03-25 2024-09-05 Jin-Woo Choi Immunoevasive anti-tumor adenovirus
CN111909962A (zh) * 2020-07-23 2020-11-10 药鼎(北京)国际细胞医学技术有限公司 一种治疗肝癌的病毒构建体及其用途和构建方法
CN118853767A (zh) * 2024-08-22 2024-10-29 华中科技大学同济医学院附属同济医院 一种新型溶瘤腺病毒载体及其构建方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002538770A (ja) * 1998-11-10 2002-11-19 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ウイルスベクターとその製造及び投与の方法
ATE291633T1 (de) * 1999-06-01 2005-04-15 Univ Washington Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration
EP1228234A2 (en) * 2000-03-14 2002-08-07 Neurologix, Inc. Production of chimeric capsid vectors
WO2005030261A1 (en) * 2003-08-28 2005-04-07 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
ES2276623B1 (es) * 2005-12-12 2008-06-01 Proyecto De Biomedicina Cima, S.L Nuevos adenovirus recombinantes de replicacion condicionada (crad).
WO2007103825A2 (en) * 2006-03-02 2007-09-13 The Board Of Regents Of The University Of Texas System Combination therapy with oncolytic adenovirus

Also Published As

Publication number Publication date
JP6280084B2 (ja) 2018-02-14
BRPI0924123B1 (pt) 2020-10-20
ZA201104224B (en) 2012-09-26
SG173432A1 (en) 2011-09-29
EP2379586B1 (en) 2016-11-02
CA2748180A1 (en) 2010-07-01
AU2009332883B2 (en) 2015-05-21
CA2748180C (en) 2017-06-20
RU2011130511A (ru) 2013-01-27
JP2016019530A (ja) 2016-02-04
BRPI0924123B8 (pt) 2021-05-25
CN102264760B (zh) 2017-03-22
WO2010072900A1 (en) 2010-07-01
KR101761094B1 (ko) 2017-08-04
RU2520823C2 (ru) 2014-06-27
AU2009332883A1 (en) 2011-07-07
CN102264760A (zh) 2011-11-30
PT2379586T (pt) 2017-02-09
CY1120039T1 (el) 2018-12-12
LT2379586T (lt) 2017-03-10
JP2012513209A (ja) 2012-06-14
HRP20170165T1 (hr) 2017-04-07
HUE031689T2 (en) 2017-07-28
PL2379586T3 (pl) 2017-08-31
DK2379586T3 (en) 2017-02-06
EP2379586A1 (en) 2011-10-26
KR20110096579A (ko) 2011-08-30
SI2379586T1 (sl) 2017-02-28

Similar Documents

Publication Publication Date Title
ES2612889T3 (es) Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos
JP7564572B2 (ja) 単離された組換え体腫瘍溶解性ワクシニアウイルスとｎｋ細胞を含む治療薬、その使用およびそれを適用したキット
CN105671083B (zh) PD‑1基因重组病毒质粒及构建、重组逆转录病毒Lenti‑PD‑1‑Puro及包装与应用
CN107793482A (zh) 嵌合抗原受体及其基因和重组表达载体、car133‑nkt 细胞及其制备方法和应用
Freeman et al. The Treatment of Ovarian Cancer with a Gene Modified Cancer Vaccine: A Phase I Study. Tulane University, New Orleans, Louisiana
CN110325200B (zh) 治疗剂及其在治疗肿瘤和/或癌症的药物中的应用
TWI439275B (zh) 一種人類自然殺手細胞之體外增殖方法
Wang et al. Combination of oxymatrine (Om) and astragaloside IV (As) enhances the infiltration and function of TILs in triple-negative breast cancer (TNBC)
CN111000851B (zh) 丹参酮i在制备肿瘤细胞自噬诱导剂药物中的应用
CN103127055A (zh) 桔皮素作为制备治疗实体瘤化疗药物增敏剂的应用
CN112661846A (zh) 一种靶向tshr的复制缺陷性重组慢病毒car-t转基因载体、其构建方法及其应用
CN110205293A (zh) 一种加强型高效治疗肺癌的nk免疫细胞的制备方法及应用
CN116712447A (zh) 淫羊藿苷在微卫星稳定型肿瘤中的应用
CN111939262A (zh) 一种治疗肿瘤或癌症的药物组合物和其应用
Rai et al. A rare case of a high-grade thymic squamous cell carcinoma presenting as cardiac tamponade
CN115350176A (zh) 一种胃癌肿瘤细胞和胃癌肿瘤干细胞治疗药物及其应用
CN113082211A (zh) 一种治疗npm1突变急性髓系白血病的药物组合物及其应用
CN118436669A (zh) 一种抗胰腺癌肿瘤药物组合物及其应用
Gansauge et al. Additional Long Antigen Exposition Dendritic Cell Therapy (LANEX-DC®) in the palliative Treatment of Stage 4 Colorectal Cancer Patients
RU2348420C2 (ru) Способ лечения местно-распространенного рака легкого
CN107693790A (zh) 用于肺癌治疗的联合药物
CN105920604A (zh) 用于治疗白血病的联合用药物及其在治疗白血病中的应用
De Sande et al. P-537 Cisplatin plus gemcitabine with or without vinorelbine as neoadjuvant therapy for radically-treatable stage II non small cell lung cancer (NSCLC). Preliminary results of a randomised study of the GON (grupo Oncológico del Norte de Espan˜ a)
CN110215460A (zh) 一种抗肿瘤的联用组合药物
HK40004557B (zh) 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途